Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
This clearance is a foundational step in Roche's commitment to enable routine clinical diagnosis with its digital pathology solutions
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
Department presents a detailed overview of the Pharma and MediTechsector and gives a detailed presentation on the activities of Department
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Subscribe To Our Newsletter & Stay Updated
